N-(2,6-dimethylphenyl)-2-pyrrolidin-1-ylacetamide;hydron;chloride | 2210-64-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2,6-dimethylphenyl)-2-pyrrolidin-1-ylacetamide;hydron;chloride
• CAS: 2210-64-2
• 化学式: C14H21ClN2O
• 分子量: 268.78
• InChiKey: FOZDSRIRBNRBDI-UHFFFAOYSA-N

物化性质

• 熔点：
  205°

计算性质

• 辛醇/水分配系数(LogP)：
  2.76
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2,6-dimethylphenyl)-2-pyrrolidin-1-ylacetamide;hydron;chloride 、 Acetic acid, mercury(2+) salt (2:1) 、 disodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate 以25%的产率得到
  参考文献：
  名称：

  VASVARI-DEBRECZY, L.;BECKETT, A. H.;VUTTHIKONGSIRIGOOL, W., TETRAHEDRON, 1981, 37, N 24, 4337-4342

  摘要：

  DOI：

文献信息

• Medicinal composition and method of making same
  申请人：Tucker, William Gough

  公开号：EP0212875A2

  公开（公告）日：1987-03-04

  There is disclosed a medicinal composition comprising lipid, non-lipid liquid and pharmaceutical ingredients, characterized by the fact that the ingredients are emulsified and encapsulated in a gelatine capsule as a liquid and in a physical form capable of delivering the pharmaceutical in its unaltered original state to the brush layer of the small intestine; the non-lipid ingredient being water, a water substitute not attacked by lipid enzyme activity or a mixture of water substitute and water; and the total water in the emulsion is not more than 20%; the physical form of the ingredients is as follows: (a) the lipid ingredient is in the form of individual globules predominantly of a size less than about 3 microns in diameter; (b) each of the globules contains the pharmaceutical ingredient dispersed therein; and (c) each of the globules is enveloped within a surrounding layer of said non-lipid liquid ingredient adhered to the globule by surface tension, the surrounding layer serving to maintain the globules in independent form and to present only the non-lipid liquid surface to the stomach fluids. There is also disclosed a method of making same.

  本发明公开了一种由脂质、非脂质液体和药物成分组成的药物组合物，其特征在于这些成分被乳化并以液体的物理形式封装在明胶胶囊中，能够以未改变的原始状态将药物输送到小肠刷状层；非脂质成分是水、未被脂质酶活性攻击的水替代物或水替代物和水的混合物；乳化液中的总水分不超过 20%；成分的物理形式如下： (a) 脂质成分主要呈直径小于约 3 微米的单个球状； (b) 每个小球都含有分散在其中的药物成分；以及 (c) 每个球状物都被包在一层非脂质液体成分的周围层中，这层液体成分通过表面张力附着在球状物上，周围层的作用是保持球状物的独立形态，并使胃液只看到非脂质液体表面。 此外，还公开了一种制作方法。
• PHARMACEUTICAL COMPOSITION USED FOR REDUCING LOCALISED FAT AND USE OF PHARMACEUTICAL COMPOSITION
  申请人：Caliway Biopharmaceuticals Co., Ltd.

  公开号：EP3381451A2

  公开（公告）日：2018-10-03

  The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

  本发明提供了一种用于减少局部脂肪的药物组合物，包括由表面活性剂制成的含药胶束和封装在所述含药胶束中的姜黄素。这种用于减少局部脂肪的药物组合物可以减少给药部位的脂肪，具有稳定性高、对脂肪组织的生物利用度高、副作用小、可持续释放等优点。
• SUBCUTANEOUS INJECTION FOR REDUCING BODY WEIGHT AND APPLICATION THEREOF
  申请人：Caliway Biopharmaceuticals Co., Ltd.

  公开号：EP3505168A1

  公开（公告）日：2019-07-03

  The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

  本发明提供了一种用于减轻体重的皮下注射制剂。该用于减轻体重的皮下注射制剂包括由聚氧乙烯蓖麻油衍生物或聚氧乙烯蓖麻油衍生物制成的含药胶束，以及封装在含药胶束中的姜黄素或姜黄素类。这种用于减轻体重的皮下注射制剂可以减轻超重或肥胖受试者的体重和内脏脂肪，具有用量少、稳定性高、脂肪组织生物利用度高、副作用小和持续释放等优点。
• Pharmaceutical composition for reducing local fat and uses thereof
  申请人：Caliway Biopharmaceuticals Co., Ltd.

  公开号：US10610496B2

  公开（公告）日：2020-04-07

  The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

  本发明提供了一种用于减少局部脂肪的药物组合物，包括由表面活性剂制成的含药胶束和封装在所述含药胶束中的姜黄素。这种用于减少局部脂肪的药物组合物可以减少给药部位的脂肪，具有稳定性高、对脂肪组织的生物利用度高、副作用小、可持续释放等优点。
• Subcutaneous injection formulation for reducing body weight and uses thereof
  申请人：Caliway Biopharmaceuticals Co., Ltd.

  公开号：US10716824B2

  公开（公告）日：2020-07-21

  The present invention provides a subcutaneous injection formulation for reducing body weight. The subcutaneous injection formulation for reducing body weight comprises drug-containing micelles made of a polyoxyethylene castor oil derivative or polyoxyethylene castor oil derivatives, and a curcuminoid or curcuminoids encapsulated in the drug-containing micelles. The subcutaneous injection formulation for reducing body weight can reduce body weight and visceral fat on overweight or obese subjects, and has the advantages of low dosage, high stability, high fat tissue bioavailability, few side effects, and sustained release.

  本发明提供了一种用于减轻体重的皮下注射制剂。该用于减轻体重的皮下注射制剂包括由聚氧乙烯蓖麻油衍生物或聚氧乙烯蓖麻油衍生物制成的含药胶束，以及封装在含药胶束中的姜黄素或姜黄素类。这种用于减轻体重的皮下注射制剂可以减轻超重或肥胖受试者的体重和内脏脂肪，具有用量少、稳定性高、脂肪组织生物利用度高、副作用小和持续释放等优点。